



Press
Release

TSXV: ADK

For immediate distribution
Source: DIAGNOS inc.

2011.01.06

DIAGNOS Announces Memorandum of Understanding with DARC for image evaluation for clinical studies and trials in the USA

Brossard, Québec, Canada – January 6, 2011 - DIAGNOS inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), a leader in the use of artificial intelligence and advanced knowledge-extraction techniques, announces today that it has signed a Memorandum of Understanding, and associated Non-Disclosure Agreement with DARC (.Digital Angiography Reading Center) as the exclusive Reading Assessment Center in the United States to use CARA in image evaluation, assessing and interpreting ophthalmic images for clinical studies and trials.

This agreement will allow DARC to increase efficiencies of screening and evaluation for patients worldwide for enrolment and clinical trials. DARC continues to utilize new advances in digital technology to expand their roll in clinical trials. Recent advances include high resolution digital color imaging, auto-fluorescent imaging, and Optical Coherence Tomography. “Now with the addition of CARA to these technologies, DARC will be in the forefront internationally for clinical trial evaluations” said Jason S. Slakter, M.D., Chairman/ President of DARC and Clinical Professor of Ophthalmology, NYU School of Medicine.

“With DARC’s expertise in color photography and their global network, this will further validate CARA’s importance in assisting eye care professionals’ worldwide in identifying diabetic retinopathy and other pathologies that in the past were difficult to see and identify” said Andre Larente, CEO of DIAGNOS.

This agreement will allow both of our organizations to structure a business relationship that jointly leverages each other’s strengths in their respective areas of business. We will also, in conjunction with DARC, evaluate the possibility of jointly developing tools and technologies for more advanced automated assessment for AMD and a Cardiology projects with imaging algorithms to predict systemic diseases in their early stages.

About DARC

As digital technology became the standard of imaging in ophthalmology, the need to apply it in a clinical trial setting was evident. The result was the creation of the Digital Angiography Reading Center (DARC), founded in 1998, the first fully digital reading center for the evaluation of ophthalmic images. DARC is a state-of-the-art facility designed to evaluate all forms of retinal imaging for clinical trials, including color and red-free photography, fluorescein and ICG angiography, SD-OCT, autofluorescence imaging, and MP1 microperimetry. DARC has extensive experience in all phases of clinical trials for a variety of retinal and macular conditions, including exudative AMD, dry AMD, DME, CRVO, BRVO, and uveitis; with a worldwide network of certified sites, photographers, and technicians.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including natural resources, healthcare, and entertainment.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com. You may also contact our investor relations manager:

André Larente, President
Telephone: 1-877-678-8882 or (450) 678-8882, ext. 224
alarente@diagnos.com